(Q57975553)

8

Dennis S. Chi

0 references

Richard R Barakat

10

Richard R. Barakat

0 references

Nadeem R. Abu-Rustum

7

Nadeem R. Abu-Rustum

0 references

Oliver Zivanovic

3

Oliver Zivanovic

0 references

William P Tew

2

William P. Tew

0 references

Paul J. Sabbatini

5

Paul J. Sabbatini

0 references

Carol Aghajanian

9

Carol Aghajanian

0 references

author name string

John P. Diaz

1

0 references

Lisa A. dos Santos

6

0 references

language of work or name

English

0 references

publication date

March 2010

0 references

published in

Gynecologic Oncology

0 references

volume

116

0 references

issue

3

0 references

page(s)

335-339

0 references

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

A reassessment of the role of second-look laparotomy in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

VEGF-targeted therapy in metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Managing patients treated with bevacizumab combination therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Intestinal perforation secondary to paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.11.017